Aerie Pharma (AERI) PT Raised to $55 at Stifel Following Analyst Day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Dow, S&P open higher as upbeat earnings obscure Mideast jitters
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- Morgan Stanley (MS) earnings beat lifts stock
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- DOJ reportedly preparing antitrust lawsuit against Live Nation, shares slide 9%
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
Aerie Pharma (AERI) PT Raised to $63 at Brean Capital
October 6, 2016 9:38 AM EDTBrean Capital analyst Difei Yang reiterated a Buy rating and listed its price target on Aerie Pharma (NASDAQ: AERI) to $63.00 (from $48.00) following yesterday's investor day.
Yang commented, "At yesterdays investor day, Aerie painted a clearer portrait of the current standard of care and competitive... More
